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1336(AEs) and immunogenicity (primary), absolute blood eosinophil
counts (cells per microliter; secondary), and annualized
exacerbation rates and asthma control questionnaire/childhood
asthma control test scores (exploratory).
Results: Over 52 weeks, 30 children received mepolizumab; 27
(90%) and 7 (23%) experienced on-treatment AEs and serious
AEs, respectively. No serious AEs were treatment related. There
were no fatal AEs. No specific patterns of AEs were evident, and
no anti-drug antibody or neutralizing antibody responses were
reported. Compared with baseline values, mepolizumab
treatment reduced blood eosinophil counts and asthma
exacerbations and improved asthma control across all treatment
groups.
Conclusion: Long-term safety, pharmacodynamic, and efficacy
data from this study support a positive benefit-risk profile for
mepolizumab in children with severe asthma with an
eosinophilic phenotype and were similar to data in studies
in adults and adolescents. (J Allergy Clin Immunol
2019;144:1336-42.)
Key words: Pediatric asthma, eosinophilia, mepolizumab
Asthma is a common pediatric condition affecting approxi-
mately 11% of children aged 6 to 12 years.1,2 Although the major-
ity of children and adolescents with asthma are able to control
their symptoms with available standard of care, up to 16% have
severe asthma and require regular treatment with high-dose
inhaled corticosteroids plus a second controller and/or chronic
systemic corticosteroids (for >_50% of the year) to manage their
condition.3,4 These children have diverse and often overlapping
phenotypes andmight continue to experience poor disease control
despite additional treatment.1,4,5 In adults a subset of patients with
severe asthma present with an eosinophilic phenotype character-
ized by airway infiltration with eosinophilic inflammatory cells,
leading to poor asthma control, frequent exacerbations, and
reduced lung function.4,6 This phenotype is associated with a
greater severity of symptoms, placing patients at greater risk of
near-fatal asthma attacks and hospitalizations or emergency
department (ED) visits.6 The eosinophilic phenotype is not well
described in children; however, eosinophils have been identified
as the predominant inflammatory cells in the airways of children
with asthma.7,8 Eosinophils persist in the airway tissue of children
with severe asthma despite use of high-dose inhaled corticoste-
roids and are associated with significant airway remodeling.5,7
Given the burden on caregivers of children with chronic illness,
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to carry a substantial health burden and reduce quality of life for
patients and their caregivers.9,10
Mepolizumab is a humanized mAb that targets IL-5, a key
regulator of eosinophil proliferation, activation, and survival.11 It
was approved in 2015 by the European Medicines Agency as an
add-on treatment for patients 18 years and older with severe
asthma with an eosinophilic phenotype and in 2018 was approved
for patients 6 years of age and older.12 In the United States mepo-
lizumab is currently approved only for adults and adolescents
12 years of age and older.13
To characterize the pharmacokinetics (PK), pharmacody-
namics, safety, and efficacy of mepolizumab in children 6 to
11 years of age with severe asthma with an eosinophilic
phenotype, a 2-part study (GSK ID 200363; NCT02377427)
was conducted in which patients received 40 or 100 mg of subcu-
taneous mepolizumab every 4 weeks according to body weight.14
The first part of the study (part A) focused on the PK and pharma-
codynamics of mepolizumab, whereas the second part (part B)
focused on long-term safety and pharmacodynamics.
Part A associated mepolizumab treatment with a favorable
safety profile in children 6 to 11 years of age.14 Average exposure
(PK) of subcutaneous mepolizumab for children was within the
acceptable range of adult target exposure, although overall, it
was greater than predicted based on adult models.14 Mepolizu-
mab treatment resulted in a marked and predictable reduction in
blood eosinophil counts compared with baseline.14
The primary objective of part B was to assess the long-term
safety of mepolizumab over an additional 52-week treatment
period in patients who successfully completed part A. The
secondary objective was to characterize the long-term pharma-
codynamics of mepolizumab.METHODS
Treatments and study design
This was an open-label, uncontrolled, repeat-dose extension to a phase II
study (GSK ID 200363/NCT02377427) conducted in children with severe
asthma with an eosinophilic phenotype. Details of the study design have
been previously published by Gupta et al.14 In Part A children 6 to 11 years
of age with severe asthma with an eosinophilic phenotype (peripheral blood
eosinophil count >_150 cells/mL at screening or >_300 cells/mL within the pre-
vious 12 months), 2 or more exacerbations in the previous 12 months, and a
well-documented requirement for regular treatment with medium or high
doses of inhaled corticosteroids (>200 mg/d fluticasone propionate or equiva-
lent plus a second controller)15 were enrolled to receive 3 doses of mepolizu-
mab every 4 weeks. Children received subcutaneous mepolizumab for
12 weeks at 40mg if theyweighed less than 40 kg or at 100mg if theyweighed
40 kg or more and were monitored for 8 weeks after treatment completion.
Children who completed all doses and assessments in part A were given theoption to continue receiving mepolizumab in part B. In this second part chil-
dren recommenced treatment to receive a further 13 doses of mepolizumab at
4-week intervals (overall study weeks 20-72).
Based on their weight at the beginning of part B (overall study week 20),
children received 40 mg of mepolizumab subcutaneously if they weighed less
than 40 kg or 100 mg subcutaneously if they weighed 40 kg or more. Children
weighing less than 40 kg at the beginning of part B were weighed at each visit,
and their dose was adjusted to 100 mg permanently once their weight reached
40 kg. On completion of all part B doses, children were given the option to
continue mepolizumab treatment within a subsequent long-term access
program (GSK ID 201956/NCT00244686).16 For thosewho chose not to tran-
sition into the long-term access program, a follow-up visit was conducted
12 weeks after their last part B dose of mepolizumab (overall study week 80).
Before inclusion in part B, children agreed to continue receiving
mepolizumab, and their parents/legal guardians were required to provide
consent. The study was performed in accordance with Good Clinical Practice
guidelines, ethical principles outlined in the Declaration of Helsinki 2008, and
institutional review board approvals/processes. Anonymized individual
participant data and study documents can be requested from www.
clinicalstudydatarequest.com.End points and assessments
Part B primary end points were the incidence of adverse events (AEs),
clinically significant changes in vital sign measurements and laboratory
parameters, and the frequency of positive anti-mepolizumab binding anti-
bodies and neutralizing antibodies. On-treatment, posttreatment, and drug-
related AEs; serious adverse events (SAEs; including fatalities); and adverse
events of special interest (AESIs) were recorded at every visit. The AESIs for
mepolizumab included systemic (allergic and nonallergic) reactions, local
injection-site reactions, cardiac disorders (serious cardiac, vascular, throm-
boembolic, and serious ischemic events), infections, neoplasms, and malig-
nancies. Vital signs were assessed at every study visit. Immunogenicity
samples were collected before dosing at overall study weeks 44 and 68 and at
follow-up week 80 for participating patients. To characterize the long-term
pharmacodynamics of mepolizumab, the secondary end point of absolute
blood eosinophil count (cells per microliter) was recorded at overall study
weeks 32, 44, 56, 68, and 72 and follow-up week 80.
Exploratory end points included asthma exacerbation frequency over the
treatment period plus changes from baseline in Asthma Control Question-
naire, 7-item (ACQ-7) or 5-item (ACQ-5), and Childhood Asthma Control
Test (C-ACT) scores at overall study weeks 32, 44, 56, 68, 72, and 80. An
exacerbation was defined as disease worsening that required systemic
corticosteroids and/or an ED visit and/or hospitalization. Annualized
exacerbation rates were compared with those calculated over the 12 months
precedingmepolizumab administration in part A. Analysis of ACQ-5 datawas
performed using the 5 symptoms item responses of the ACQ-7 questionnaire.Comparison with adult/adolescent studies
Asthma exacerbation rates and changes from baseline in ACQ-5 scores at
the end of treatment were compared with those of the corresponding adult and
adolescent data from mepolizumab phase II b/3 trials (Dose Ranging Efficacy
And Safety With Mepolizumab in Severe Asthma [DREAM; MEA112997/
NCT01000506], Mepolizumab as Adjunctive Therapy in Patients with Severe
Asthma [MENSA; MEA115588/NCT01691521], Mepolizumab Adjunctive
Therapy in Subjects with Severe Eosinophilic Asthma [MUSCA; 200862/
NCT02281318], and the Steroid Reduction with Mepolizumab Study
[SIRIUS; MEA115575/NCT01691508]) to contextualize the exploratory effi-
cacy data observed in this study.17-19Statistical analysis
This article contains a complete analysis of the long-term data collected
within part B; all part A data have been published previously.14 The sample
size for part Awas determined by the number of children needed for adequate
PK and pharmacodynamic evaluations based on previous studies.14 Therefore
TABLE I. Summary of patients’ demographics and baseline characteristics
Mepolizumab,
40 mg (n 5 16)
Mepolizumab,
100 mg (n 5 10)
Mepolizumab,
40/100 mg* (n 5 4)
Mepolizumab,
total (n 5 30)
Derived age (y) 7.5 (1.6) 10.0 (1.3) 9.3 (1.5) 8.6 (1.9)
Sex, no. (%)
Male 12 (75) 5 (50) 3 (75) 20 (67)
Female 4 (25) 5 (50) 1 (25) 10 (33)
Race, no. (%)
Asian 5 (31) 1 (10) 1 (25) 7 (23)
Black or African American 2 (13) 3 (30) 2 (50) 7 (23)
White 8 (50) 6 (60) 1 (25) 15 (50)
Multiple 1 (6) 0 0 1 (3)
Weight (kg) 27.5 (3.9) 52.5 (6.6) 34.1 (7.8) 36.2 (12.5)
Body mass index (kg/m2) 16.1 (1.3) 23.5 (2.7) 16.8 (4.0) 18.5 (4.0)
Pre-BD lung function§
FEV1 (mL) 1381 (370) 1940 (310) 1583 (541) 1594 (444)
Predicted normal FEV1 (%) 89.5 (15.14) 92.3 (6.94) 87.7 (28.50) 90.2 (14.84)
FVC 1759 (387.0) 2436 (448.4) 2098 (329.7) 2030 (499.2)
FEV1/FVC ratio 0.79 (0.109) 0.80 (0.091) 0.74 (0.148) 0.79 (0.107)
No. of exacerbations requiring corticosteroids in 12 mo
before screening, median (range)§
2.5 (2-6) 2.0 (2-10) 4.5 (3-8) 2.5 (2-10)
Patients with an exacerbation requiring hospitalization
in 12 mo before screening, no. (%)§
8 (50) 2 (20) 2 (50) 12 (40)
Blood eosinophil count (cells/mL), geometric
mean (SD log)§
306 (0.807) 331 (0.910) 506 (0.085) 336 (0.789)
ACQ-7 score§ 1.83 (1.01) 1.39 (0.96) 2.64 (1.23) 1.79 (1.06)
ACQ-5 score§ 1.94 (1.03) 1.42 (1.09) 2.75 (1.59) 1.87 (1.17)
C-ACT score§ 16.4 (5.3) 20.4 (3.2) 15.8 (4.3) 17.6 (4.9)
Data are means (SDs), unless otherwise stated.
BD, Bronchodilator; FVC, forced vital capacity.
*These patients weighed less than 40 kg and received 40 mg of mepolizumab at the start of part B and were moved to the 100 mg treatment group when their weight reached 40 kg
or greater.
Only year of birth was collected, with age derived by using an imputed birth date of June 30th.
Data are from the latest value recorded before the first dose of mepolizumab in part B of the study.
§Data are from the latest value recorded before the first dose of mepolizumab in part A of the study.
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enrolled and treated in part Awho were eligible for and willing to participate
in Part B. All statistical analyses were performed by using the safety popula-
tion (all children who received >_1 dose of mepolizumab within part B). End
points were summarized by using appropriate descriptive statistics (mean/geo-
metric mean, median, SD, and range).
AEs were summarized by using the Medical Dictionary for Regulatory
Activities Primary System Organ Class and Preferred Terms. Annualized
exacerbation rates were determined by using a negative binomial generalized
linear model with logarithm of time as an offset variable, from which estimated
rates per year and 95% CIs were calculated. For blood eosinophil counts, the
ratio to baseline was summarized by visit; if a result of zero was recorded, a
small value (half the minimum nonzero result) was imputed before log-
transformation. For blood eosinophil counts and asthma control questionnaire
scores, baseline was defined as the value recorded before the first mepolizumab
treatment in part A (overall study week 0). All statistical analyses were
performed with SAS software (version 9.4; SAS Institute, Cary, NC).RESULTS
Patient population
Of the 36 children enrolled in part A, 30 (83%) consented to
take part in part B; 2 eligible children decided not to enter part B,
and 4 were not eligible because they did not complete part A (see
Fig E1 in this article’s Online Repository at www.jacionline.org).
A total of 29 (97%) children completed part B; 1 was withdrawn
from the study because of a protocol deviation of poor compliancewith study visits and study medication. Demographic and base-
line characteristics are shown in Table I. The mean age was 8.6
(SD, 1.9) years, and 20 (67%) of the children were male. At the
start of part B, the mean weight was 36.2 kg (SD, 12.5); 4 children
weighing less than 40 kg at part B screening reached 40 kg or
greater during part B, resulting in permanent adjustment of their
mepolizumab dose from 40 to 100 mg administered subcutane-
ously. In part B most children (90%) received all 13 treatments
and spent an average of 355 days on treatment, with exposure
to mepolizumab amounting to 29.2 patient years.Safety
Across all part B treatment groups, on-treatment AEs were
reported in 27 (90%) children (Table II), the most frequent of
which were bronchitis (9 children), headache (8 children), and
asthma exacerbation (7 children). Of the 27 children experiencing
on-treatment AEs during the 52-week treatment period, 8 (27%)
experienced an on-treatment AE that was considered related to
mepolizumab by the investigator; these included headache (4
children), upper abdominal pain (3 children), and pyrexia (2 chil-
dren). The majority of on-treatment AEs were moderate in inten-
sity. Eight on-treatment AEs did not resolve by the end of the
study; one of these (mild upper abdominal pain) was considered
related to mepolizumab.
TABLE II. Summary of AEs and immunogenicity
Patients, no. (%)
Mepolizumab,
40 mg (n 5 16)
Mepolizumab,
100 mg (n 5 10)
Mepolizumab,
40/100 mg* (n 5 4)
Mepolizumab,
total (n 5 30)
Any AE 15 (94) 8 (80) 4 (100) 27 (90)
On-treatment AEs 15 (94) 8 (80) 4 (100) 27 (90)
Posttreatment AEs 5 (31) 4 (40) 0 9 (30)
Treatment-related§ on-treatment AEs 4 (25) 3 (30) 1 (25) 8 (27)
AEs leading to discontinuation of treatment or
withdrawal
0 0 0 0
Most frequent on-treatment AEs (>10% of total population)
Bronchitis 5 (31) 3 (30) 1 (25) 9 (30)
Headache 4 (25) 3 (30) 1 (25) 8 (27)
Asthma 4 (25) 2 (20) 1 (25) 7 (23)
Nasopharyngitis 3 (19) 1 (10) 2 (50) 6 (20)
Upper respiratory tract infection 2 (13) 2 (20) 1 (25) 5 (17)
Influenza 3 (19) 0 1 (25) 4 (13)
Any SAE 4 (25) 2 (20) 1 (25) 7 (23)
On-treatment SAEs 4 (25) 2 (20) 1 (25) 7 (23)
Posttreatment SAEs 1 (6) 1 (10) 0 2 (7)
Treatment-related§ on-treatment SAEs 0 0 0 0
Fatal SAEs 0 0 0 0
On-treatment AESIs
Systemic reactions 1 (6) 1 (10) 0 2 (7)
Allergic hypersensitivity (anaphylactic shockk
and generalized rash)
1 (6) 1 (10) 0 2 (7)
Nonallergic 0 0 0 0
Local injection-site reactions 0 0 0 0
All infections 11 (69) 7 (70) 4 (100) 22 (73)
Serious 0 1 (10) 0 1 (3)
Opportunistic 0 1 (10) 0 1 (3)
Neoplasms 0 0 0 0
Malignancies 0 0 0 0
Cardiac disorders 0 0 0 0
Serious CVT events 0 0 0 0
Serious ischemic events 0 0 0 0
ADA assay result
Negative 16 (100) 10 (100) 4 (100) 30 (100)
Positive# 0 0 0 0
AEs were summarized by using the Medical Dictionary for Regulatory Activities Primary System Organ Class and Preferred Terms.
CVT, Cardiac, vascular, and thromboembolic.
*These patients weighed less than 40 kg and received 40 mg of mepolizumab at the start of part B and were moved to the 100 mg treatment group when their weight reached 40 kg
or greater.
Any AE commencing within 4 weeks of the last dose of mepolizumab.
AEs commencing more than 4 weeks after the last mepolizumab dose.
§As assessed by the treating investigator.
kAnaphylactic shock was due to a previously diagnosed peanut allergy and was not considered related to mepolizumab treatment by the investigator.
#A patient’s results were considered ‘‘positive’’ if they had at least 1 positive postbaseline ADA assay result within part B of the study.
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related to mepolizumab by the investigator, were reported in 7
(23%) children; these resolved without interruption of mepo-
lizumab treatment. Asthma exacerbation (5 children) was the
only on-treatment SAE reported in more than 1 child. On-
treatment SAEs reported by 1 child each included anaphylactic
shock, epistaxis, and pneumonia. The SAE of anaphylactic
shock occurred in a 6-year-old boy in the group receiving
40 mg of mepolizumab subcutaneously 27 days after his fifth
part B dose of mepolizumab and was determined to be caused
by a previously diagnosed peanut allergy. The SAE of
pneumonia occurred in a 10-year-old girl 25 days after her
second part B dose of mepolizumab. Two additional SAEs
were reported after treatment (wheezing and asthmaexacerbation) and were not considered related to mepolizumab
treatment. No fatal SAEs were reported (Table II).
A comparison of these SAE rates with those from adult and
adolescent studies is shown in Table E1 in this article’s Online
Repository at www.jacionline.org.
On-treatment AESIs are outlined in Table II. Two children
reported systemic reactions; 1 (anaphylactic shock) was judged
by the investigator to be a serious event and is described
above. One child in the group receiving 100 mg of mepolizu-
mab subcutaneously (a 10-year-old boy) had an event of
moderate-intensity body rash with pruritis 3 days after his final
dose of mepolizumab in part B. This was judged to be related
to mepolizumab treatment but was not deemed serious. On-
treatment infections were reported in 22 (73%) children, the
TABLE III. Summary of blood eosinophils (cells/mL)
Time point in part B (within the overall study)
Blood eosinophils (cells/mL), geometric mean (SD log)
Mepolizumab,
40 mg (n 5 16)
Mepolizumab,
100 mg (n 5 10)
Mepolizumab,
40/100 mg* (n 5 4)
Mepolizumab,
total (n 5 30)
Baseline (week 0) 306 (0.807) 331 (0.910) 506 (0.085) 336 (0.789)
Week 12 (week 32) 52 (0.820) 58 (0.796) 37 (0.696) 52 (0.784)
Week 24 (week 44) 51 (0.712) 63 (0.772) 74 (1.495) 58 (0.839)
Week 36 (week 56) 48 (0.642) 57 (0.597) 29 (0.767) 48 (0.656)
Week 48 (week 68) 47 (1.090) 71 (0.647) 55 (1.473) 55 (0.995)
Week 52 (week 72) 48 (0.858) 44 (1.020) 49 (0.166) 47 (0.841)
Week 60 (week 80; follow-up) 164 (0.973) 199 (1.666) NA 179 (1.274)
NA, Not available.
*These patients weighed less than 40 kg and received 40 mg of mepolizumab at the start of part B and were moved to the 100 mg treatment group when their weight reached 40 kg
or greater.
Baseline was defined as the latest value recorded before the first dose of mepolizumab in part A.
Week 80 was not applicable to patients transitioning to the long-term access program.
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nasopharyngitis, upper respiratory tract infection, and influ-
enza. One child (a 10-year-old girl) had an event of pneumonia
25 days after her second part B dose of mepolizumab, which
was not judged to be related to mepolizumab treatment. One
child (a 10-year-old boy) had 2 on-treatment events of oral
herpes, which were not judged to be related to mepolizumab
treatment or to represent invasive disease/opportunistic infec-
tion. No children reported local injection-site reactions, neo-
plasms, malignancies, or cardiac events. Throughout part B,
there were no apparent treatment-related changes in clinical
laboratory parameters, electrocardiographic results, or vital
signs (data not shown).Immunogenicity
No anti-drug antibody (ADA) or neutralizing antibody re-
sponses were reported throughout part B (Table II). Of the 2 chil-
dren with positive ADA responses in part A, one did not continue
into part B, and the other was ADA negative throughout part B.Pharmacodynamics
The baseline geometric mean blood eosinophil count (collected
before the first mepolizumab treatment in part A) across all 30
patients enrolled in part B was 336 cells/mL. Geometric mean
blood eosinophil counts were reduced to approximately 50 to
60 cells/mL at the first time point measured in part B (preceding
the fourth part B dose of mepolizumab, Table III), and this reduc-
tion was sustained through the cessation of treatment at overall
study week 72 (Fig 1 and Table III). In children followed up to
week 80 (12 weeks since the last dose), blood eosinophil counts
began to increase toward but did not reach baseline values (Fig
1 and Table III).Efficacy
Asthma control improved relative to baseline through part B, as
indicated by improvements in ACQ-7, ACQ-5, and C-ACT scores
(see Fig E2 and Table E2 in this article’s Online Repository at
www.jacionline.org). Before receiving mepolizumab in part A,
children’s mean ACQ-7, ACQ-5, and C-ACT scores were 1.79
(95% CI, 1.39-2.19), 1.87 (95% CI, 1.44-2.31), and 17.6 (95%CI, 15.8-19.4), respectively. Part B improvements in asthma con-
trol were greatest at week 36 (overall study week 56), with mean
scores reaching 0.79 (95% CI, 0.51-1.06), 0.79 (95% CI, 0.51-
1.07), and 22.0 (95% CI, 20.7-23.3), respectively. At week 52,
4 weeks after the last dose of mepolizumab, mean scores were
1.14 (95% CI, 0.79-1.49), 1.08 (95% CI, 0.64-1.52), and 20.5
(95% CI, 18.8-22.2), respectively.
A minimal clinically important difference (MCID) of at least
0.5 points from baseline ACQ-7 and ACQ-5 scores was met by
55% and 59% of children, respectively, at week 52 (overall study
week 72, see Table E2). This was similar to ACQ-5 score im-
provements observed in older patients, with 42% to 59% of adults
and adolescents achievingMCIDs from baseline ACQ-5 scores at
the end of mepolizumab treatment (see Table E3 in this article’s
Online Repository at www.jacionline.org).
Fourteen (47%) children had 1 or more on-treatment exacer-
bations during part B (see Table E4 in this article’s Online Repos-
itory at www.jacionline.org), 5 of whom required an ED visit or
hospitalization. Annualized on-treatment exacerbation rates
were lower than baseline for all treatment groups, with the annu-
alized on-treatment rate (1.09 events/y [95%CI, 0.63-1.89 events/
y]) representing a 69% decrease from the 12 months before part
A screening (a mean of 3.5 events). On-treatment exacerbation
rates reported for children in part B are similar to those reported
in adults and adolescents receiving mepolizumab, which range
from 0.51 to 1.44 events/y (see Table E3). Overall, 28 (93%) chil-
dren experienced at least a 25% reduction, 24 (80%) experienced
at least a 50% reduction, and 18 (60%) experienced at least a 75%
reduction in exacerbations (see Table E4). Children reported
greater on-treatment rates of exacerbations requiring hospitaliza-
tion than adults and adolescents, with children reporting a mean
of 0.21 events/y (95% CI, 0.08-0.55 events/year) and adults and
adolescents reporting means of 0.02 to 0.10 events/year (see
Tables E3 and E4).DISCUSSION
This was a long-term (52-week) study of mepolizumab in
children 6 to 11 years of age with severe asthma with an
eosinophilic phenotype. The safety data (including SAEs) from
part B demonstrate that mepolizumab was well tolerated, with a
safety profile consistent with that of part A14 and similar to that
observed in previous studies of adults and adolescents.17-20
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FIG 1. Geometric mean ratio to baseline (defined as the latest value recorded before the first dose of
mepolizumab in part A) of blood eosinophil counts throughout parts A and B. Vertical bars represent 95%
CIs, and dashed lines indicate the start of the follow-up period in each study part. Week 80 was not appli-
cable to patients transitioning to the long-term access program. BL, Baseline; SC, subcutaneous.
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whereas exploratory analyses suggested improvements in asthma
control similar to those observed in adults and adolescents.17-19
The safety and tolerability of mepolizumab in part B of the
study was consistent with that in part A. No new safety concerns
were observed after long-term treatment with mepolizumab in
children compared with adults and adolescents with severe
asthma and an eosinophilic phenotype.14,17-19,21 Also in line
with previous long-term observations in adults and adolescents,21
the incidence of reported local injection-site reactions decreased
over time; 5 children reported reactions in part A, and no reactions
were reported in part B. Positive immunogenicity samples were
infrequent across parts A and B, with no positive immunogenicity
results in part B. This is consistent with the low immunogenicity
observed in adults and adolescents after treatment with mepolizu-
mab, suggesting a low or limited immune response to mepolizu-
mab in children.17-19,21,22
In terms of pharmacodynamic responses, blood eosinophil
counts began to increase after cessation of treatment at the end of
part A; in previous adult and adolescent studies this response has
been associated with a worsening of asthma symptoms (as
indicated by ACQ-7 and ACQ-5 scores).22,23 After reinitiation
of mepolizumab treatment in part B, blood eosinophil counts
again began to decrease. The sustained reduction in blood eosin-
ophil counts (to 50 cells/mL) observed during the 12-week dosing
phase of mepolizumab in part A14 was reproduced during the
long-term, 52-week dosing phase in part B. This reduction in
blood eosinophil counts after treatment with 40 or 100 mg of sub-
cutaneous mepolizumab is also consistent with blood eosinophil
counts achieved in adult/adolescent studies (approximately
40 cells/mL) across a 10-fold range of doses (75–750 mg) and
differing administration routes (subcutaneous or intravenous),
suggesting that higher doses might not reduce blood eosinophil
counts further.17,19,24
In the exploratory analysis of efficacy data, reduced on-
treatment exacerbation rates observed in children appear to be
consistent with those noted previously in adults and adoles-
cents,17-19 withmean annualized rates reduced to approximately 1
event/y after mepolizumab treatment in both age groups with this
highly exacerbating asthma phenotype. As expected, there was a
greater frequency of on-treatment asthma exacerbations during
part B compared with part A because of the longer study durationof part B. However, annualized exacerbation rates in part B were
considerably lower than rates in the 12 months before screening
for each treatment group, with 80% of children at least halving
their exacerbation rates compared with pretreatment values.
Although annualized exacerbation rates recorded before and
during mepolizumab treatment within this study are similar to
those previously reported in adults and adolescents, the hospital-
ization rate appears to be higher.17-19,21 This is likely due to dif-
ferences in hospitalization criteria for children and adolescents
compared with adults25,26 because the children enrolled in this
study presented with baselinemarkers of disease (eg, blood eosin-
ophil counts and lung function) similar to those reported in the
equivalent adult and adolescent studies. This also highlights
that as a vulnerable patient population, children with severe
asthma with an eosinophilic phenotype are more likely to be hos-
pitalized than adults presenting with similar symptoms during an
exacerbation.27
Improvements in asthma control were observed in children
receiving mepolizumab treatment (as indicated by ACQ and
C-ACT scores). At the end of treatment, approximately 40% to
60% of both children and adults/adolescents met MCIDs
indicative of disease improvement.17-19 Additionally, consistency
observed across ACQ-7, ACQ-5, and C-ACT responses
throughout both parts of this study provides reassurance that
asthma control parameters evaluated by using ACQ and C-ACT
questionnaires proportionately reflect symptom control in chil-
dren with severe asthma, as suggested by previous comparisons
of these tools.28
There are several limitations to this study that should be
acknowledged. This was an open-label study in children aged 6 to
11 years to assess the PK, pharmacodynamics, and safety profiles
of mepolizumab in children with severe asthma with an
eosinophilic phenotype, and therefore no direct comparator was
available. A double-blind, placebo-controlled randomized trial is
difficult to perform in this patient population because of the rarity
of the disease phenotype in this age group.12 Moreover, it can be a
difficult decision for parents to enroll their children in a clinical
trial, making enrollment particularly challenging. Therefore the
efficacy data from this study have been compared with those of
the corresponding adult/adolescent program, in which these chal-
lenges are less prevalent, and consequently, a more adequate sam-
ple size could be enrolled.17-19 This comparison can be
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applied across the studies, irrespective of age.
When reviewing the results, it should be noted that the small
sample size and uncontrolled design of this study limited further
assessments of efficacy. Additionally, because the part B follow-
up period was not required for children transitioning to the long-
term access program (Study 201956), the posttreatment observa-
tion period for these children was of limited length.
In conclusion, the results of this long-term study suggest that
mepolizumab is well tolerated after 52 weeks of continuous
treatment in children 6 to 11 years of age with severe asthma with
an eosinophilic phenotype. Importantly, safety data generated
by part B indicate that mepolizumab administered at a body
weight–dependent dose of 40 or 100 mg administered
subcutaneously has an acceptable safety profile for long-term
use in children with peripheral blood eosinophil counts of
150 cells/mL or greater (or >_300 cells/mL in the previous
12 months). Although limited, the uncontrolled efficacy data in
children 6 to 11 years of age appeared to be consistent with
adult/adolescent efficacy data. The PK in part A and the
pharmacodynamics and safety profiles of mepolizumab in
both parts of this study appear to be similar to those found in
adults and adolescents, supporting the extrapolation of
mepolizumab treatment efficacy data from adults and adolescents
to children.
Clinical implications: These safety, pharmacodynamic, and ef-
ficacy data support long-term mepolizumab use in children 6
to 11 years of age with severe asthma with an eosinophilic
phenotype and are similar to those reported in adults/
adolescents.REFERENCES
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Mepolizumab 40 mg
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 intervention (n=16)
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Mepolizumab 40/100 mg†
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• Lost to follow-up (n=0)
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FIG E1. Summary of patient disposition for parts A and B. Treatment group allocated according to body
weight: 40 mg (<40 kg) and 100 mg (>_40 kg). *Child withdrew because of an AE of asthma. These patients
weighed less than 40 kg and received 40mg ofmepolizumab at the start of part B andweremoved to the 100
mg mepolizumab subcutaneous treatment group when their weight reached 40 kg or greater.
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FIG E2. Mean change from baseline (defined as the latest value recorded
before the first dose of mepolizumab in part A) in ACQ-7 and ACQ-5 scores
(A) and C-ACT scores (B) throughout part B. Vertical bars represent 95% CIs,
and dashed lines indicate the start of the part B follow-up period. Week 60
was not applicable to patients transitioning to the long-term access pro-
gram. BL, Baseline; SC, subcutaneous.
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TABLE E1. Comparison of SAEs in study 200363 and adolescent/adult data from the mepolizumab clinical development
programE1,E2,E3,E4
Study size Study duration (wk) Placebo Mepolizumab (all doses)
Patients experiencing SAEs, no. (%)
Children
200363, part B 30 52* NA 7 (23)
Adults/adolescents
DREAM 616 52 25 (16) 63 (14)
MENSA 576 32 27 (14) 30 (8)
MUSCA 551 24 22 (8) 15 (5)
SIRIUS 135 24 12 (18) 1 (1)
Patients experiencing treatment-related SAEs, no. (%)
Children
200363, part B 30 52* NA 0
Adults/adolescents
DREAM 616 52 0 2 (<1)
MENSA 576 32 1 (<1) 1 (<1)
MUSCA 551 24 1 (<1) 0
SIRIUS 135 24 0 0
DREAM, Mepolizumab for Severe Eosinophilic Asthma; MENSA, Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma; MUSCA, Mepolizumab Adjunctive
Therapy in Subjects with Severe Eosinophilic Asthma; NA, not applicable; SIRIUS, Steroid Reduction with Mepolizumab Study.
*Duration of study B only (total duration of parts A and B was 80 weeks).
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TABLE E2. Summary of exploratory efficacy end points during
part B
Time point in part B
(within the overall study)
Mean change from
baseline* (95% CI)
Patients meeting
MCID from baseline,*
no. (%)
ACQ-7
Week 12 (week 32) 20.54 (20.94 to 20.15) 15/29 (52)
Week 24 (week 44) 20.49 (20.79 to 20.18) 13/28 (46)
Week 36 (week 56) 20.93 (21.34 to 20.51) 19/29 (66)
Week 48 (week 68) 20.77 (21.15 to 20.40) 18/29 (62)
Week 52 (week 72) 20.57 (21.04 to 20.10) 16/29 (55)
Week 60 (week 80;
follow-up)
20.49 (20.92 to 20.07) 12/23 (52)
ACQ-5
Week 12 (week 32) 20.66 (21.15 to 20.16) 17/29 (59)
Week 24 (week 44) 20.59 (20.97 to 20.21) 14/28 (50)
Week 36 (week 56) 21.03 (21.52 to 20.53) 20/29 (69)
Week 48 (week 68) 20.90 (21.34 to 20.47) 19/29 (66)
Week 52 (week 72) 20.73 (21.32 to 20.14) 17/29 (59)
Week 60 (week 80;
follow-up)
20.57 (21.07 to 20.08) 11/23 (48)
C-ACT
Week 12 (week 32) 2.3 (0.8 to 3.8) NA
Week 24 (week 44) 3.4 (1.6 to 5.1) NA
Week 36 (week 56) 4.0 (2.3 to 5.7) NA
Week 48 (week 68) 4.0 (2.4 to 5.7) NA
Week 52 (week 72) 2.5 (0.9 to 4.1) NA
Week 60 (week 80;
follow-up)
2.3 (0.8 to 3.8) NA
The MCID of ACQ scores was defined as a 0.5-point or greater reduction.
NA, Not available.
*Baseline was defined as the latest value recorded before the first dose of
mepolizumab in part A.
Week 80 was not applicable to patients transitioning to the long-term access
program.
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TABLE E3. Comparison of efficacy data from study 200363 and adolescent/adult data from the mepolizumab clinical development
programE1,E2,E3,E4
Study size Study duration (wk) Placebo Mepolizumab (all doses)
Annualized rate of on-treatment exacerbations (95% CI)
Children
200363, part B 30 52* NA 1.09 (0.63-1.89)
Adults/adolescents
DREAM 616 52 2.40 (1.95-2.95) 1.28 (1.11-1.48)
MENSA 576 32 1.74 (1.44-2.11) 0.88 (0.74-1.04)
MUSCA 551 24 1.21 (1.01-1.46) 0.51 (0.39-0.65)
SIRIUS 135 24 2.12 (1.66-2.70) 1.44 (1.08-1.93)
Annualized rate of on-treatment exacerbations requiring hospitalization (95% CI)
Children
200363, part B 30 52* NA 0.21 (0.08-0.55)
Adults/adolescents
DREAM 616 52 0.18 (0.10-0.32) 0.10 (0.06-0.16)
MENSA 576 32 0.10 (0.05-0.20) 0.05 (0.02-0.09)
MUSCA 551 24 0.07 (0.03-0.15) 0.02 (0.01-0.07)
SIRIUS 135 24 Not estimable Not estimable
>_0.5-Point reduction from baseline in ACQ-5 score at end of treatment, no. (%) of patients
Children
200363, part B 30 52* NA 17/29 (59)
Adults/adolescents
DREAM 616 52 77/153 (50) 222/452 (49)
MENSA 576 32 85/186 (46) 202/373 (54)
MUSCA 551 24 116/276 (42) 161/274 (59)
SIRIUS 135 24 19/66 (29) 29/69 (42)
DREAM, Mepolizumab for Severe Eosinophilic Asthma; MENSA, Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma; MUSCA, Mepolizumab Adjunctive
Therapy in Subjects with Severe Eosinophilic Asthma; NA, not available; SIRIUS, Steroid Reduction with Mepolizumab Study.
*Duration of study part B only (total duration of study parts A and B was 80 weeks).
Insufficient events reported to estimate an exacerbation rate.
Patients with missing ACQ-5 scores at baseline have been excluded.
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TABLE E4. Summary of on-treatment exacerbations
Mepolizumab,
40 mg (n 5 16)
Mepolizumab,
100 mg (n 5 10)
Mepolizumab,
40/100 mg* (n 5 4)
Mepolizumab,
total (n 5 30)
Any exacerbation
Children, no. (%) 8 (50) 3 (30) 3 (75) 14 (47)
No. of events 11 12 8 31
Annualized rate
Mean rate/year (95% CI) 0.76 (0.34-1.68) 1.20 (0.51-2.83) 1.98 (0.58-6.79) 1.09 (0.63-1.89)
Reduction from baseline, no. (%)
>_25% 14 (88) 10 (100) 4 (100) 28 (93)
>_50% 13 (81) 8 (80) 3 (75) 24 (80)
>_75% 10 (63) 7 (70) 1 (25) 18 (60)
100% 8 (50) 7 (70) 1 (25) 16 (53)
Exacerbations requiring hospitalization/ED visit
Children, no. (%) 2 (13) 2 (20) 1 (25) 5 (17)
No. of events 2 5 1 8
Exacerbations requiring hospitalization
Children, no. (%) 2 (13) 2 (20) 1 (25) 5 (17)
No. of events 2 3 1 6
Annualized rate
Mean rate/y (95% CI) 0.14 (0.03-0.62) 0.30 (0.08-1.08) 0.25 (0.03-2.19) 0.21 (0.08-0.55)
*These patients weighed less than 40 kg and received 40 mg of mepolizumab at the start of part B and were moved to the 100 mg treatment group when their weight reached 40 kg
or more.
Baseline defined as the exacerbation rate calculated from the 12 months before screening in part A of the study.
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